Author

D. Speidel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. Nist· 2 shared J. Cinatl· 2 shared M. Mernberger· 2 shared M. Michaelis· 2 shared T. Stiewe· 2 shared A. von Deimling· 1 shared C. Harper-Wynne· 1 shared C. Schneider· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Nist

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Resistance patterns in drug-adapted cancer cell lines reflect complex evolution in clinical tumors

H. E. Grimsley, M. Antczak, I. G. Reddin, K.-M. McLaughlin, A. Nist, M. Mernberger, T. Stiewe, T. R. Fenton, D. Speidel, C. Harper-Wynne, K. Cox, J. Cinatl, M. N. Wass, M. Garrett, M. Michaelis

This study identifies drug-resistant sublines of TNBC cell lines and finds that resistance mechanisms are unique and unpredictable, suggesting new potential drug targets.

bioRxiv · Jan 20, 2024 · PreprintCancer Biology

TP53 mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistance

M. Michaelis, C. Schneider, F. Rothweiler, T. Rothenburger, M. Mernberger, A. Nist, A. von Deimling, D. Speidel, T. Stiewe, J. Cinatl

This study establishes MDM2 inhibitor-resistant AML sub-lines and finds that resistance arises from pre-existing TP53 mutations or de novo mutations, with variable drug sensitivity despite loss of p53 function.

bioRxiv · Aug 30, 2018 · PreprintPharmacology & Toxicology